CB‐012 (NCT06128044) is a gene editing technology from Caribou Biosciences using in‐house Cas12a chRDNA gene editing technology, CLL‐1 (CD371) is expressed on the surface of AML tumor cells and leukemia stem cells, but not on normal HSCs and could be a therapeutic target for AML. Here, CLEC12A is linked to leukemia.